Perindopril monotherapy and PROGRESS in Europe

Comment

Richard Wennberg et al. BMJ. 2005.

. 2005 Jul 23;331(7510):235-6.

doi: 10.1136/bmj.331.7510.235-b.

No abstract available

Figures

The PROGRESS trial three years later: time for a balanced report of effectiveness.
Wennberg R, Zimmermann C. Wennberg R, et al. BMJ. 2004 Oct 23;329(7472):968-70. doi: 10.1136/bmj.329.7472.968. BMJ. 2004. PMID: 15499116 Free PMC article.
The PROGRESS trial three years later: time for more action, less distraction.
Macmahon S, Neal B, Rodgers A, Chalmers J. Macmahon S, et al. BMJ. 2004 Oct 23;329(7472):970-1. doi: 10.1136/bmj.329.7472.970. BMJ. 2004. PMID: 15499117 Free PMC article. No abstract available.

1. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with a previous stroke or transient ischaemic attack. Lancet 2001;358: 1033-41. - PubMed
1. Bobbio M, Della Penna V, Tarascio A. Inchiesta sull'indicazione terapeutica del perindopril. Dall'evidence based medicine all'advertisment based medicine. Occhio Clinico 2005;3: 6.
1. MacMahon S, Neal B, Rodgers A, Chalmers J. Commentary. The PROGRESS trial three years later: time for more action, less distraction. BMJ 2004;329: 970-1. - PMC - PubMed
1. Wennberg R, Zimmermann C. The PROGRESS trial three years later: time for a balanced report of effectiveness. BMJ 2004;329: 968-70. - PMC - PubMed